Federal Register / Vol. 74, No. 77 / Thursday, April 23, 2009 / Notices 18577 

Missouri Federal Savings Bank (to be 

known as 1st Cameron State Bank), both 

of Cameron, Missouri, upon its 

conversion to a commerical bank. 

Board of Governors of the Federal Reserve 

System, April 20, 2009. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E9–9310 Filed 4–22–09; 8:45 am] 

BILLING CODE 6210–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects: 

Title: Tribal TANF Data Report, TANF 

Annual Report, and Reasonable Cause/ 

Corrective Action Documentation 

Process- Final. 

OMB No.: 0970–0215. 

Description: 42 U.S.C. 612 (Section 

412 of the Social Security Act as 

amended by Public Law 104–193, the 

Personal Responsibility and Work 

Opportunity Reconciliation Act of 1996 

(PRWORA)), mandates that Federallyrecognized Indian Tribes with approved 

Tribal TANF program collect and 

submit to the Secretary of the 

Department of Health and Human 

Services data on the recipients served 

by the Tribe’s programs. This 

information includes both aggregated 

and disaggregated data on case 

characteristics and individual 

characteristics. In addition, Tribes that 

are subject to a penalty are allowed to 

provide reasonable cause justifications 

as to why a penalty should not be 

imposed or may develop and implement 

corrective compliance procedures to 

eliminate the source of the penalty. 

Finally, there is an annual report, which 

requires the Tribes to describe program 

characteristics. All of the above 

requirements are currently approved by 

OMB and the Administration for 

Children and Families is simply 

proposing to extend them without any 

changes. 

Respondents: Indian Tribes. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden 

hours 

per 

response 

Total 

burden hours 

Final Tribal TANF Data Report ........................................................................ 62 4 451 111,848 

Tribal TANF Annual Report ............................................................................. 62 1 40 2,480 

Tribal TANF Reasonable Cause/Corrective .................................................... 62 1 60 3,720 

Estimated Total Annual Burden 

Hours: 118,048. 

In compliance with the requirements 

of Section 506(c)(2)(A) of the Paperwork 

Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. E-mail address: 

infocollection@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Dated: April 20, 2009. 

Janean Chambers, 

Reports Clearance Officer. 

[FR Doc. E9–9340 Filed 4–22–09; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Request for Nominations of 

Candidates To Serve on the Board of 

Scientific Counselors, Coordinating 

Office for Terrorism Preparedness and 

Emergency Response (BSC, COTPER) 

CDC is soliciting nominations for 

possible membership on the BSC, 

COTPER. This board provides advice 

and guidance to the Secretary, 

Department of Health and Human 

Services (HHS), the Director, CDC, and 

the Director, COTPER, concerning 

strategies and goals for the programs 

and research within the divisions; 

conducts peer-review of scientific 

programs; and monitors the overall 

strategic direction and focus of the 

divisions. 

Nominations are being sought for 

individuals who have the expertise and 

qualifications necessary to contribute to 

the accomplishment of the board’s 

objectives. Nominees will be selected by 

the Secretary, HHS, or designee, from 

authorities knowledgeable in the fields 

relevant to the issues addressed by the 

offices and divisions within the 

coordinating office and related 

disciplines, including: Medicine, 

epidemiology, laboratory science, 

informatics, behavioral science, social 

science, engineering, business, and 

crisis leadership. Members may be 

invited to serve for terms of up to four 

years. Consideration is given to 

representation from diverse geographic 

areas, both genders, ethnic and minority 

groups, and the disabled. Nominees 

must be U.S. citizens. 

The following information must be 

submitted for each candidate: Name, 

affiliation, address, telephone number, 

e-mail address, and current curriculum 

vitae. Nominations should be 

accompanied by a letter of 

recommendation stating the 

qualifications of the nominee and must 

be postmarked by May 11, 2009 to: 


sroberts on PROD1PC70 with NOTICES
18578 Federal Register / Vol. 74, No. 77 / Thursday, April 23, 2009 / Notices 

Matthew Jennings, BSC Coordinator, 

CDC, Coordinating Office for Terrorism 

Preparedness and Emergency Response, 

1600 Clifton Road, NE., Mailstop D–44, 

Atlanta, Georgia 30333, Telephone (404) 

639–7357. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities for both CDC and 

the Agency for Toxic Substances and 

Disease Registry. 

Dated: April 17, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Service 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–9331 Filed 4–22–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Draft National Institutes of Health 

Guidelines for Human Stem Cell 

Research Notice 

SUMMARY: The National Institutes of 

Health (NIH) is requesting public 

comment on draft guidelines entitled 

‘‘National Institutes of Health 

Guidelines for Human Stem Cell 

Research’’ (Guidelines). 

The purpose of these draft Guidelines 

is to implement Executive Order 13505, 

issued on March 9, 2009, as it pertains 

to extramural NIH-funded research, to 

establish policy and procedures under 

which NIH will fund research in this 

area, and to help ensure that NIHfunded research in this area is ethically 

responsible, scientifically worthy, and 

conducted in accordance with 

applicable law. Internal NIH 

procedures, consistent with Executive 

Order 13505 and these Guidelines, will 

govern the conduct of intramural NIH 

research involving human stem cells. 

These draft Guidelines would allow 

funding for research using human 

embryonic stem cells that were derived 

from embryos created by in vitro 

fertilization (IVF) for reproductive 

purposes and were no longer needed for 

that purpose. Funding will continue to 

be allowed for human stem cell research 

using adult stem cells and induced 

pluripotent stem cells. Specifically, 

these Guidelines describe the conditions 

and informed consent procedures that 

would have been required during the 

derivation of human embryonic stem 

cells for research using these cells to be 

funded by the NIH. NIH funding for 

research using human embryonic stem 

cells derived from other sources, 

including somatic cell nuclear transfer, 

parthenogenesis, and/or IVF embryos 

created for research purposes, is not 

allowed under these Guidelines. 

NIH funding of the derivation of stem 

cells from human embryos is prohibited 

by the annual appropriations ban on 

funding of human embryo research 

(Consolidated Appropriations Act, 2009, 

Pub. L. 110–161, 3/11/09), otherwise 

known as the Dickey-Wicker 

Amendment. 

According to these Guidelines, there 

are some uses of human embryonic stem 

cells and human induced pluripotent 

stem cells that, although those cells may 

come from allowable sources, are 

nevertheless ineligible for NIH funding. 

For questions regarding ongoing NIHfunded research involving human 

embryonic stem cells, as well as 

pending applications and those 

submitted prior to the issuance of Final 

Guidelines, see the NIH Guide http:// 

grants.nih.gov/grants/guide/notice-files/ 

NOT-OD-09-085.html. 

DATES: Written comments must be 

received by NIH on or before May 26, 

2009. 

ADDRESSES: The NIH welcomes public 

comment on the draft Guidelines set 

forth below. Comments may be entered 

at: http://nihoerextra.nih.gov/ 

stem_cells/add.htm. Comments may 

also be mailed to: NIH Stem Cell 

Guidelines, MSC 7997, 9000 Rockville 

Pike, Bethesda, Maryland 20892–7997. 

Comments will be made publicly 

available, including any personally 

identifiable or confidential business 

information they contain. 

SUPPLEMENTARY INFORMATION: On March 

9, 2009, President Barack H. Obama 

issued Executive Order 13505: 

Removing Barriers to Responsible 

Scientific Research Involving Human 

Stem Cells. The Executive Order states 

that the Secretary of Health and Human 

Services, through the Director of NIH, 

may support and conduct responsible, 

scientifically worthy human stem cell 

research, including human embryonic 

stem cell research, to the extent 

permitted by law. 

The purpose of these draft Guidelines 

is to implement Executive Order 13505, 

issued on March 9, 2009, as it pertains 

to extramural NIH-funded research, to 

establish policy and procedures under 

which NIH will fund research in this 

area, and to help ensure that NIHfunded research in this area is ethically 

responsible, scientifically worthy, and 

conducted in accordance with 

applicable law. Internal NIH 

procedures, consistent with Executive 

Order 13505 and these Guidelines, will 

govern the conduct of intramural NIH 

research involving human stem cells. 

Long-standing Department of Health 

and Human Services regulations for 

Protection of Human Subjects, 45 CFR 

part 46, establish safeguards for 

individuals who are the sources of many 

human tissues used in research, 

including non-embryonic human adult 

stem cells and human induced 

pluripotent stem cells. When research 

involving human adult stem cells or 

induced pluripotent stem cells 

constitutes human subject research, 

Institutional Review Board review may 

be required and informed consent may 

need to be obtained per the 

requirements detailed in 45 CFR part 46. 

Applicants should consult http:// 

www.hhs.gov/ohrp/humansubjects/ 

guidance/45cfr46.htm. 

As described in these draft 

Guidelines, human embryonic stem 

cells are cells that are derived from 

human embryos, are capable of dividing 

without differentiating for a prolonged 

period in culture, and are known to 

develop into cells and tissues of the 

three primary germ layers. Although 

human embryonic stem cells are derived 

from embryos, such stem cells are not 

themselves human embryos. 

Studies of human embryonic stem 

cells may yield information about the 

complex events that occur during 

human development. Some of the most 

serious medical conditions, such as 

cancer and birth defects, are due to 

abnormal cell division and 

differentiation. A better understanding 

of the genetic and molecular controls of 

these processes could provide 

information about how such diseases 

arise and suggest new strategies for 

therapy. Human embryonic stem cells 

may also be used to test new drugs. For 

example, new medications could be 

tested for safety on differentiated 

somatic cells generated from human 

embryonic stem cells. 

Perhaps the most important potential 

use of human embryonic stem cells is 

the generation of cells and tissues that 

could be used for cell-based therapies. 

Today, donated tissues and organs are 

often used to replace ailing or destroyed 

tissue, but the need for transplantable 

tissues and organs far outweighs the 

available supply. Stem cells, directed to 

differentiate into specific cell types, 

offer the possibility of a renewable 

source of replacement cells and tissues 

to treat diseases and conditions, 

including Parkinson’s disease, 

amyotrophic lateral sclerosis, spinal 

cord injury, burns, heart disease, 

diabetes, and arthritis. 


sroberts on PROD1PC70 with NOTICES